{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Schneider EK"],"funding":["National Institute of Allergy and Infectious Diseases","NIAID NIH HHS","Cystic Fibrosis Foundation","National Health and Medical Research Council"],"pagination":["478-88"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5300747"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["2(7)"],"pubmed_abstract":["Novel combination therapies are desperately needed for combating lung infections caused by bacterial \"superbugs\". This study aimed to investigate the synergistic antibacterial activity of polymyxin B in combination with the cystic fibrosis (CF) drugs KALYDECO (ivacaftor) and ORKAMBI (ivacaftor + lumacaftor) against Gram-negative pathogens that commonly colonize the CF lung, in particular, the problematic Pseudomonas aeruginosa. The in vitro synergistic activity of polymyxin B combined with ivacaftor or lumacaftor was assessed using checkerboard and static time-kill assays against a panel of polymyxin-susceptible and polymyxin-resistant P. aeruginosa isolates from the lungs of CF patients. Polymyxin B, ivacaftor, and lumacaftor were ineffective when used individually against polymyxin-resis"],"journal":["ACS infectious diseases"],"pubmed_title":["An \"Unlikely\" Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI."],"pmcid":["PMC5300747"],"funding_grant_id":["R01 AI111965","R01 AI104895","R01AI104895","R01AI111965"],"pubmed_authors":["Li J","Doi Y","Han ML","Wang J","Huang JX","Azad MA","Velkov T","Schneider EK","Cooper MA","Muller MT","Tony Zhou Q","Baker MA","Bergen PJ"],"additional_accession":[]},"is_claimable":false,"name":"An \"Unlikely\" Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI.","description":"Novel combination therapies are desperately needed for combating lung infections caused by bacterial \"superbugs\". This study aimed to investigate the synergistic antibacterial activity of polymyxin B in combination with the cystic fibrosis (CF) drugs KALYDECO (ivacaftor) and ORKAMBI (ivacaftor + lumacaftor) against Gram-negative pathogens that commonly colonize the CF lung, in particular, the problematic Pseudomonas aeruginosa. The in vitro synergistic activity of polymyxin B combined with ivacaftor or lumacaftor was assessed using checkerboard and static time-kill assays against a panel of polymyxin-susceptible and polymyxin-resistant P. aeruginosa isolates from the lungs of CF patients. Polymyxin B, ivacaftor, and lumacaftor were ineffective when used individually against polymyxin-resis","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Jul","modification":"2025-04-19T22:41:46.925Z","creation":"2019-03-27T02:36:11Z"},"accession":"S-EPMC5300747","cross_references":{"pubmed":["27626100"],"doi":["10.1021/acsinfecdis.6b00035"]}}